Navigation Links
American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
Date:2/3/2011

SHIRLEY, N.Y., Feb. 3, 2011 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the consumer and user level of the following product:

Sodium Thiosulfate Injection, USP, 10% (100 mg/mL), 10 mL Single Dose Vial
NDC # 0517-1019-05
Lot #0056
Exp Date:  January, 2012



PLEASE NOTE:  This recall, initiated on February 2, 2011 to the User or Consumer Level, is for lot # 0056 Only. No other lots or sizes of Sodium Thiosulfate Injection, USP are subject to this voluntary recall.

This voluntary recall was initiated because some vials of this lot exhibit translucent visible particles consistent with glass delamination.  Glass delamination can occur with high pH solutions when the surface glass from the vial separates into thin layers, resulting in glass particles with a flaky appearance.

Potential adverse events after intravenous administration include damage to blood vessels in the lung, localized swelling, and granuloma formation.  American Regent is undertaking this recall in consideration of the potential for safety issues if this lot of product is administered to patients.

Sodium Thiosulfate Injection, USP is indicated in the treatment of cyanide poisoning.

The product was distributed to wholesalers and distributors nationwide.

Hospitals, Emergency Rooms, Infusion Centers, Clinics and other healthcare facilities should not use American Regent Inc., Sodium Thiosulfate Injection, USP, 10% (100mg/mL) 10 mL Single Dose Vial with lot # 0056 for patient care and should immediately quarantine any product for return.

American Regent is notifying its distributors and consumers by email, facsimile and/or overnight courier and is arranging for return of all recalled product.  Consumers/distributors/retailers that have product which is being recalled should stop use.

American Regent will credit accounts for all returned product with this lot #. Those with questions about the return or recall process, please call our Customer Service Department at 1-877-788-3232: Monday thru Friday from 8:30AM to 7:00PM ET.

Hospitals, emergency rooms, infusion centers, clinics and healthcare providers, or patients with product quality complaints, medical or other questions concerning the use of the product or reasons for this recall should contact the Professional Services Department at 1-877-788-3232.

Any adverse reactions experienced with the use of this product should be reported to American Regent, Inc. via email at pv@luitpold.com, by fax to (610) 650-7781 or (610) 650-0170 or by phone at 1-800-734-9236.  TO EXPEDITE HANDLING PLEASE DO NOT REPORT ANYTHING OTHER THAN SPECIFIC ADVERSE EVENTS TO THIS EMAIL ADDRESS OR FAX OR PHONE.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.



  • Fax: 1-800-FDA-0178

"All of us at Luitpold Pharmaceuticals and American Regent are committed to taking the necessary steps to protect patients from any potential safety risks with our Sodium Thiosulfate Injection. The safety of patients receiving our products is our primary concern," said Mary Jane Helenek, President and CEO of American Regent.

While American Regent continues to investigate this issue, the company is taking precautionary action and initiated this voluntary recall.  American Regent has informed the FDA of its actions and is maintaining ongoing discussions with the agency.

As is standard practice, and as stated in the Sodium Thiosulfate Injection, USP Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

Sodium Thiosulfate Injection, USP is manufactured by Luitpold Pharmaceuticals, Inc. and is distributed by American Regent, Inc. (Shirley, NY).

This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration.


'/>"/>
SOURCE Luitpold Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... , ... Cosmetic surgeon Dr. Mark Youssef first introduced Voluma® to his ... his menu of services to give his patients as many options as possible in ... improving his approach to ensure he stays at the forefront of the most modern ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... Texas (PRWEB) , ... May 03, 2016 , ... Park ... that live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, ... Lawn/Uptown, Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities ...
(Date:5/3/2016)... ... May 03, 2016 , ... Octo Consulting ... and digital consulting services to the federal government, has been awarded a $9.9 ... Indefinite Quantity (ID/IQ) contract in support of the U.S. Army Program Executive Office ...
(Date:5/3/2016)... California (PRWEB) , ... May ... ... leading provider of Microsoft secure remote access connectivity solutions, today announced the ... platform for Microsoft DirectAccess. The new Celestix SecureAccess release will enable organizations ...
Breaking Medicine News(10 mins):